Cochlear Chairman, Rick Holliday-Smith, to Head QBiotics Board

Australian life sciences company QBiotics Limited today announced the appointment of Rick Holliday-Smith as its new Non-Executive Chairman.

In accepting the appointment Mr. Holliday-Smith said: “I have been a QBiotics shareholder for some time and have watched the technology develop as QBiotics has matured. In my view QBiotics is set to make a significant contribution to the future treatment of cancer and wounds in animals and humans, a contribution that I want to make Australian-centred to the fullest extent possible. To me, QBiotics is another example of great Australian inquisitiveness and innovation. I look forward to being part of optimizing the value of the company and securing its future as an important contributor to the Australian economy. As we move towards a world increasingly focused on new ideas and technology, these are the type of Australian businesses we need to nurture and support”. Among his current senior leadership roles, Mr. Holliday-Smith is Chairman of the Australian Securities Exchange (ASX) and Non-Executive Chairman of Cochlear Limited (COH).  He is also a Non-Executive Director of Servcorp Limited (SRV). His extensive board career spans close to 20 years and included long term positions including SFE Corporation Limited, MIA Group Limited, Exco Resources Limited and Macquarie University Faculty of Business and Economics. Previously he held several global leadership positions in the finance industry including CEO of Chicago Research and Trading (CRT), President for global trading and sales at Nations Bank-CRT and Managing Director of London based HongKong Bank Limited. QBiotics CEO and Managing Director, Dr. Victoria Gordon, said “We are delighted that Mr. Holliday-Smith has agreed to join QBiotics.  Rick brings a wealth of invaluable corporate experience to the Chairman’s position at a critical time for our company.  With our technology progressing towards commercialisation, I am sure Rick’s sage advice will support us to maximize the value of our products for QBiotics, our shareholders and the Australian community”. “We continue to make progress in veterinary and human trials of our anticancer drug EBC-46 and we are on the verge of securing access to significant markets in the veterinary space. This parallel progress in both the veterinary and human spheres will underpin the long term success of the company”. QBiotics is an Australian public unlisted company. To receive more information please click the button below.

To download the full announcement, please click on the link below.